CD86 and neoplasm: While various lymphocyte co-stimulatory molecules, such as major histocompatibility complex (MHC) class I and II molecules, CD83, CD86, and CD40 on CD11c+CD103+ DCs within tumours of mice treated with PAK4 inhibitors, did not show statistically significant differences compared to control mice, there were trend toward increased expression levels.